Edition:
United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

1.28USD
13 Dec 2018
Change (% chg)

$-0.07 (-5.19%)
Prev Close
$1.35
Open
$1.35
Day's High
$1.35
Day's Low
$1.26
Volume
11,661
Avg. Vol
45,768
52-wk High
$4.50
52-wk Low
$1.09

Chart for

About

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combinatio... (more)

Overall

Beta: 0.81
Market Cap(Mil.): $27.16
Shares Outstanding(Mil.): 35.79
Dividend: --
Yield (%): --

Financials

  HTBX.OQ Industry Sector
P/E (TTM): -- 69.71 34.39
EPS (TTM): -0.44 -- --
ROI: -114.78 9.01 14.96
ROE: -175.18 10.15 16.52

Heat-stable drug could save thousands from post-childbirth bleeding: WHO

LONDON A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).

Jun 27 2018

Heat-stable drug could save thousands from post-childbirth bleeding - WHO

LONDON, June 27 A new formulation of a drug to prevent excessive bleeding in women after they give birth could save thousands of lives in poorer countries, according to a study co-led by the World Health Organization (WHO).

Jun 27 2018

Earnings vs. Estimates